The next wave of diagnostics that can scan a patient’s DNA for a host of genetic diseases needs to be better regulated to ensure the tests deliver what they promise, according to the FDA. Those regulators’ struggle to exert oversight could inform upcoming legislation to give the FDA even more authority.
Next-generation sequencing can screen millions of DNA changes in a single test, unlike traditional diagnostics that link one test to one disease. These powerful genomic tests are the linchpin to advancing precision medicine, an emerging approach for disease prevention and treatment that targets care based on an individual’s genes, ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.